Vaccine Therapy in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer

Status unconfirmed · Phase 2

Conditions studied: Lung Cancer

In brief

RATIONALE: Vaccines made from peptides may make the body build an effective immune response to kill tumor cells. PURPOSE: This phase II trial is studying how well vaccine therapy works in treating patients with stage IIIB, stage IV, or recurrent non-small cell lung cancer.

Key facts

Study ID

NCT00104780

Run by

Epimmune

Starts

2004-12-01

Last updated by the study team

2013-11-06

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Cancer Centers of Florida - Ocoee — Ocoee, Florida, United States
• New York Oncology Hematology, P. C. at Albany Regional Cancer Care — Albany, New York, United States
• Duke Comprehensive Cancer Center — Durham, North Carolina, United States
• Dayton Oncology & Hematology, P.A. - Kettering — Kettering, Ohio, United States
• Cancer Centers of the Carolinas - Eastside — Greenville, South Carolina, United States
• Sarah Cannon Cancer Center at Centennial Medical Center — Nashville, Tennessee, United States
• Mary Crowley Medical Research Center at Sammons Cancer Center — Dallas, Texas, United States
• Tyler Cancer Center — Tyler, Texas, United States
• Cancer Care Northwest - North — Spokane, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.